Wnukowski-Mtonga Peter, Jayasinghe Sanjay, Chiu Clayton, Macartney Kristine, Brotherton Julia, Donovan Basil, Hall Madeline, Smith David W, Peterson Karen, Campbell-Lloyd Sue, Selvey Christine, Giles Michelle, Kaldor John, Marshall Helen
National Centre for Immunisation Research and Surveillance, Westmead, New South Wales.
National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, The Children's Hospital at Westmead Clinical School, University of Sydney, Sydney, New South Wales.
Commun Dis Intell (2018). 2020 Apr 15;44. doi: 10.33321/cdi.2020.44.33.
The Australian Technical Advisory Group on Immunisation (ATAGI) updated recommendations on the use of human papillomavirus (HPV) vaccines in the Australian Immunisation Handbook in 2018, regarding the use of the recently available 9-valent (9vHPV) vaccine, Gardasil 9, and a 2-dose schedule for young adolescents for HPV vaccines. This report provides an overview of the relevant scientific evidence that underpinned these updated recommendations. The 9vHPV vaccine includes 5 HPV types (HPV 31, 33, 45, 52 and 58) additional to the 4 that are also covered by the 4vHPV (Gardasil) vaccine (HPV 6,11,16,18). Accordingly, the 9vHPV vaccine is expected to prevent an additional 15% of cervical cancers and up to 20% of other HPV-related cancers. Non-inferior antibody responses after two 9vHPV vaccine doses given 6-12 months apart in girls and boys aged 9-14 years compared to women aged 16-26 years after three doses support the 2-dose schedule for adolescents of this age group. In clinical trials 9vHPV vaccine was well-tolerated with a similar safety profile to 4vHPV vaccine. The switch to 9vHPV vaccine and a 2-dose schedule is anticipated to improve public acceptability of the program and reduce HPV-related disease in the long-term.
澳大利亚免疫技术咨询小组（ATAGI）于2018年更新了《澳大利亚免疫手册》中关于人乳头瘤病毒（HPV）疫苗使用的建议，涉及最新可用的9价（9vHPV）疫苗佳达修9以及青少年HPV疫苗的2剂接种程序。本报告概述了支撑这些更新建议的相关科学证据。9vHPV疫苗除了涵盖4价HPV（佳达修）疫苗（HPV 6、11、16、18）所包含的4种HPV类型外，还包括另外5种HPV类型（HPV 31、33、45、52和58）。因此，预计9vHPV疫苗可额外预防15%的宫颈癌和高达20%的其他HPV相关癌症。9至14岁的女孩和男孩间隔6至12个月接种两剂9vHPV疫苗后的抗体反应与16至26岁女性接种三剂后的抗体反应非劣效，这支持了该年龄组青少年的2剂接种程序。在临床试验中，9vHPV疫苗耐受性良好，安全性与4vHPV疫苗相似。改用9vHPV疫苗和2剂接种程序有望提高该计划的公众接受度，并长期减少HPV相关疾病。
